Springer Healthcare’s Post

🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗜 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟   Join Prof Eric Van Cutsem and Prof Marc Van den Eynde in 'What's New Doc?' as they discuss the groundbreaking CodeBreak 300 trial, combining sotorasib with panitumumab in KRAS G12C mutated metastatic colorectal cancer patients. Tune in now!   👇 Watch all WND GI videos - link in the comments! #MediMix #GastricCancer #Immunotherapy #OncologyResearch

The oncology space is dynamic, with many novel interventions undergoing clinical trials. Today, we dive into the EXAM study, a Phase III clinical trial conducted by Exelixis to assess the progression-free survival (PFS) with cabozantinib vs. placebo in patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). #Oncology #MetastaticMedullaryThyroidCancer #CancerTreatment #EXAMStudy #ClinitalTrials #Cabozantinib

👀 Watch the replay to get insight on the findings of the most anticipated abstracts presented on hepatocellular carcinoma at the recent #esmo World GI Congress and #asco23 Annual Meeting. https://lnkd.in/eSPCm2Kv #hepatology #oncology

✨ Key takeaways from ASCO 2024 The American Society of Clinical Oncology (ASCO) Annual Meeting is a major conference where oncologists from around the world gather to unveil the latest research and innovations. This meeting uncovered exciting insights on breast cancer that we compiled in our latest blog. Read the key highlights covering groundbreaking predictive testing, drug developments, clinical trial updates, and more 👉 https://lnkd.in/egPa8gEq #asco2024 #breastcancer #oncology #cancersupport #digitalhealthstartup

🚀 ASCO 2024 In Depth: Exciting news in the treatment of Melanoma! Prof Dr Caroline Robert shares the primary results of the phase II EBIN study, evaluating an induction treatment with dual BRAF+MEK inhibition followed by immunotherapy before disease progression in patients with BRAF-mutated advanced melanoma. The trial showed: - No PFS difference between the induction strategy and upfront immunotherapy in unselected patients. - A suggestion for a PFS benefit with targeted therapy induction in patients with a very high baseline LDH level and in patients with liver metastases. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #Melanoma #Oncology #CancerTreatment

Delivering chemo via HER2- and Trop2-targeted Antibody-drug conjugates (ADCs) has reshaped the way we treat Metastatic breast cancer (MBC) - Paolo Tarantino Ilana Schlam #cancer #chemotherapy #antibodydrug #europeaninstituteofofoncology #metastaticcancer #researcher #oncology #oncodaily

This week, our spotlight is on a pivotal study assessing the efficacy of tebentafusp in patients with metastatic uveal melanoma. The phase 3 trial revealed a significant improvement in overall survival for individuals treated with tebentafusp compared to standard therapies, with a median survival of 21.6 months versus 16.9 months in the control group. Notably, 27% of patients receiving tebentafusp were alive at three years, surpassing the 18% survival rate of the control group. This trial underscores tebentafusp's potential as a promising treatment option, offering a meaningful survival advantage for HLA-A*02:01–positive patients with this challenging cancer. The study was selected by Dr. Lara Valeska Maul-Duwendag, one of the Oncology Compass Scientific Leaders, and can be found here: https://lnkd.in/dq9VBJzW #melanoma #oncology

👋 🙌 LIVE from ESMO - European Society for Medical Oncology congress ! Tebentafusp shows sustained benefit in metastatic uveal melanoma Latest findings on tebentafusp were presented, including 3-year survival data from the pivotal phase III trial and insights from a real-world study. Long-term follow-up data from this study were presented at the Congress, revealing a 3-year OS rate of 27% for tebentafusp compared with 18% for patients treated with the investigator’s choice of therapy (mostly single-agent pembrolizumab, some ipilimumab or dacarbazine) (LBA50).  More information on https://lnkd.in/eYivTv8h #oncology #cancer #tebentafusp #Immunocore #Uveal melanoma #melanoma

Approximately 36% of patients diagnosed with lung cancer receive the correct treatment. The AMCP Market Insights Best Practice webinar brings together Daryl Pritchard, Precision Medicine Coalition, and Susan Wescott, Mayo Clinic to discuss the key findings of the market insights roundtable on gaps that exist in the precision medicine side of non-small cell lung cancer (NSLC). View the NSLC Best Practice webcast today: https://bit.ly/4efCk4W #oncology #lungcancer #managedcare #pharmacy

This week’s practice-changing study looks at the extended follow-up of the phase 3, randomized, open-label CLEAR study which evaluated lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment in advanced renal cell carcinoma. Patients who had not received any systemic anticancer therapy were eligible and were randomly assigned to receive either the combination of lenvatinib and pembrolizumab, or sunitinib. The primary endpoint was progression-free survival. Results from the extended follow-up confirm that lenvatinib plus pembrolizumab provides durable and clinically meaningful benefits over sunitinib, thus supporting its use as a first-line therapy for patients with advanced renal cell carcinoma. This study was selected by Dr. Richard Cathomas, one of the Oncology Compass Scientific Leaders, and can be found on our website: https://lnkd.in/dUADmZp2 #cancerresearch #oncology #oncologyresearch